https://sputniknews.in/20240330/ukraine-used-as-testing-ground-for-major-western-pharmaceutical-companies-document-6991075.html
Ukraine Used as Testing Ground for Major Western Pharmaceutical Companies: Document
Ukraine Used as Testing Ground for Major Western Pharmaceutical Companies: Document
Sputnik India
Ukraine served as a primary testing location for a drug linked to different types of cancer, which was administered to patients at a hospital in Mariupol... 30.03.2024, Sputnik India
2024-03-30T14:48+0530
2024-03-30T14:48+0530
2024-03-30T14:48+0530
ukraine conflict
ukraine
mariupol
denmark
health
special military operation
ukraine armed forces
biological weapons
https://cdn1.img.sputniknews.in/img/07e7/08/10/3637958_0:107:1024:683_1920x0_80_0_0_73a59d2db101666f1ec52d476793e272.jpg
Ukraine was one of the main testing grounds for trials of a drug that could potentially cause various forms of cancer and that was used on patients in the psychiatric ward of Mariupol Hospital No. 7 with the support of local officials in the interests of Western pharmaceutical companies, according to documents seen by Sputnik.In particular, the trial involved the experimental drug SB4 for the treatment of rheumatoid arthritis. The drug inhibits the action of molecules of the so-called tumor necrosis factor alpha (TNF-α), which plays an important role in the immune system, and its use creates the possibility of developing various forms of cancer, including in the lymphatic and hematopoietic systems, as well as skin.The manufacturers of SB4 were Biogen Idec Denmark Manufacturing ApS (Denmark), Catalent Pharma Solutions (Belgium), and Fisher Clinical Services UK Limited (UK). The study was sponsored by South Korea's Samsung Bioepis, the documents read.An application from Quintiles Ukraine for approval by the state expert center of the Ukrainian Ministry of Health and the Ethics Commission at the medical and preventive institution for conducting clinical trials of SB4 was found among the documents. Quintiles Ukraine was established as a division of the US outsourcing pharmaceutical company Quintiles Transnational.According to the application, signed in February 2013, at that time it was planned to test the drug in Ukraine on 152 patients (later this number increased to 180), and in total on almost 500 patients around the world.
https://sputniknews.in/20240323/western-support-transforms-ukraine-into-european-terrorism-hub-russian-fm-6926702.html
ukraine
mariupol
denmark
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2024
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_IN
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
ukraine, mariupol, denmark, health, special military operation, ukraine armed forces, biological weapons
ukraine, mariupol, denmark, health, special military operation, ukraine armed forces, biological weapons
Ukraine Used as Testing Ground for Major Western Pharmaceutical Companies: Document
Ukraine served as a primary testing location for a drug linked to different types of cancer, which was administered to patients at a hospital in Mariupol., Sputnik has revealed.
Ukraine was one of the main testing grounds for trials of a drug that could potentially cause various forms of cancer and that was used on patients in the psychiatric ward of Mariupol Hospital No. 7 with the support of local officials in the interests of Western pharmaceutical companies, according to documents seen by Sputnik.
In particular, the trial involved the experimental drug SB4 for the treatment of rheumatoid arthritis. The drug inhibits the action of molecules of the so-called tumor necrosis factor alpha (TNF-α), which plays an important role in the immune system, and its use creates the possibility of developing various forms of cancer, including in the lymphatic and hematopoietic systems, as well as skin.
The manufacturers of SB4 were Biogen Idec Denmark Manufacturing ApS (Denmark), Catalent Pharma Solutions (Belgium), and Fisher Clinical Services UK Limited (UK). The study was sponsored by South Korea's Samsung Bioepis, the documents read.
An application from Quintiles Ukraine for approval by the state expert center of the Ukrainian Ministry of Health and the Ethics Commission at the medical and preventive institution for conducting clinical trials of SB4 was found among the documents. Quintiles Ukraine was established as a division of the US outsourcing pharmaceutical company Quintiles Transnational.
According to the application, signed in February 2013, at that time it was planned to test the drug in Ukraine on 152 patients (later this number increased to 180), and in total on almost 500 patients around the world.
.jpg){kind=link}